Huang Yu Ling, Dickerson Lindsay K, Kenerson Heidi, Jiang Xiuyun, Pillarisetty Venu, Tian Qiang, Hood Leroy, Gujral Taranjit S, Yeung Raymond S
Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Department of Surgery, University of Washington, Seattle, WA, USA.
BME Front. 2023 Jun 16;4:0022. doi: 10.34133/bmef.0022. eCollection 2023.
In the era of personalized oncology, there have been accelerated efforts to develop clinically relevant platforms to test drug sensitivities of individual cancers. An ideal assay will serve as a diagnostic companion to inform the oncologist of the various treatments that are sensitive and insensitive, thus improving outcome while minimizing unnecessary toxicities and costs. To date, no such platform exists for clinical use, but promising approaches are on the horizon that take advantage of improved techniques in creating human cancer models that encompass the entire tumor microenvironment, alongside technologies for assessing and analyzing tumor response. This review summarizes a number of current strategies that make use of intact human cancer tissues as organotypic cultures in drug sensitivity testing.
在个性化肿瘤学时代，人们加快了开发临床相关平台以测试个体癌症药物敏感性的步伐。理想的检测方法将作为诊断辅助手段，告知肿瘤学家哪些治疗敏感、哪些不敏感，从而在将不必要的毒性和成本降至最低的同时改善治疗结果。迄今为止，尚无此类可供临床使用的平台，但前景广阔的方法即将出现，这些方法利用了在创建涵盖整个肿瘤微环境的人类癌症模型方面的改进技术，以及评估和分析肿瘤反应的技术。本综述总结了一些当前在药物敏感性测试中利用完整人类癌组织作为器官型培养物的策略。
